The FDA has granted acceptance for a new drug application (NDA) concerning the combination therapy of avutometinib and defactinib for patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC). This significant step, taken under the accelerated approval pathway, aims to provide a treatment option for adults who have undergone at least one prior systemic therapy.
If approved, this combination could become the first FDA-sanctioned treatment specifically targeting recurrent KRAS-mutant LGSOC. The NDA was finalized in October 2024, with the Prescription Drug User Fee Act (PDUFA) action date set for June 30, 2025. Verastem Oncology, the company behind the application, expressed optimism about the potential impact of this treatment.
Addressing Unmet Needs
Dan Paterson, the president and CEO of Verastem Oncology, emphasized the critical demand for effective therapies in this challenging medical landscape. The acceptance of the NDA signals hope for patients afflicted by this rare and insidious form of ovarian cancer. The company is eager to provide a groundbreaking treatment option in the United States.
Low-grade serous ovarian cancer is notorious for its high recurrence rates and limited response to conventional chemotherapy, particularly when compared to high-grade serous ovarian cancer. Approximately 6,000 to 8,000 women in the United States, and around 80,000 worldwide, are currently battling this ailment, which typically affects younger women in two age brackets: 20 to 30 and 50 to 60 years. The median survival rate for LGSOC patients is roughly 10 years.
A New Treatment Paradigm
Currently, there are no approved therapies specifically designed for this type of ovarian cancer, which presents distinct biological characteristics and treatment responses compared to its high-grade counterpart. The proposed combination of avutometinib and defactinib offers a new avenue for patients who currently have no adequate treatment options.
The NDA was supported by data from the phase 2 RAMP 201 clinical trial, which assessed the efficacy of the combination in patients with recurrent LGSOC. Preliminary results were presented during the International Gynecologic Cancer Society Annual Global Meeting in October 2024. Findings indicated promising responses to the investigational therapy.
Promising Clinical Data
The phase 2 RAMP 201 study demonstrated a significant overall response rate for the combination therapy, confirmed through blinded independent central review. Notably, patient responses were often durable, and the regimen was generally well-tolerated among those with recurrent KRAS-mutant LGSOC.
Avutometinib functions as an oral RAF/MEK clamp, inhibiting MEK1/2 kinase activities and forming inactive complexes with other kinases, which enhances the anti-tumor response. In contrast, defactinib selectively inhibits Focal Adhesion Kinase (FAK) and proline-rich tyrosine kinase-2, contributing to the therapeutic effect.
Comprehensive Trial Design
The adaptive, two-part multicenter RAMP 201 trial was designed to evaluate both the safety and efficacy of the combination therapy. The first part of the trial determined that the combination of avutometinib and defactinib was superior to avutometinib alone based on overall response rates. Subsequent parts assessed the safety profile and efficacy of the regimen, administering avutometinib at a dose of 3.2 mg twice weekly and defactinib at 200 mg twice daily. A further part of the study is currently exploring a lower dose of the combination to tailor treatment plans.
Future Directions
Verastem Oncology is simultaneously enrolling patients with recurrent disease—irrespective of KRAS mutation status—in the international phase 3 RAMP 301 trial. This study aims to serve as a confirmatory investigation for the initial indication and may pave the way for expanded treatment options beyond KRAS mutations.
Paterson concluded with optimism, highlighting that the NDA acceptance marks a pivotal advancement in addressing a long-neglected condition. The company looks forward to collaborating with the FDA throughout the review process and preparing for a potential commercial launch in mid-2025.
Key Takeaways
- The FDA has accepted an NDA for the combination of avutometinib and defactinib targeting KRAS-mutated low-grade serous ovarian cancer.
- This therapy could be the first FDA-approved treatment specifically for recurrent KRAS-mutant LGSOC patients.
-
Clinical trials show promising efficacy and safety, potentially offering a new standard of care for this challenging disease.
In summary, the acceptance of this NDA represents a critical milestone in oncology, enhancing hopes for patients battling a challenging form of cancer. As research progresses, the potential for innovative treatments continues to expand, offering renewed optimism for those affected.
Read more → www.curetoday.com